Tuesday, September 28
Medtech by the Numbers
Venture capital fundraising boomed in 1H 2021. Investment into companies spiked to new records as well. This overview will review activity in venture healthcare in the first half of 2021, focusing on medical device investment and exit activity. This overview will review the top device indications by deals and dollars, the most active investors, and explore M&A and IPO activity, highlighting key trends in the sector.
Unicorns, IPOs, and SPACs – Perspectives on the Recent Historic Run of Mega-Deals
Company Building at a Time of Unprecedented Change and Uncertainty
1. Leveraging RWE to Grow Your Business with a High-Multiple ROI
2. Special Considerations for Strategic Investments and AcquisitionsLearn the pros and cons of structuring a strategic investment from experienced Medtech CEOs, along with guidance regarding governance, control, protection of intellectual property and additional rights often associated with strategic investments and acquisitions.
3. Preparing to Be a Public Medtech Company and Investor Communications StrategiesKeynote 1:1 Interview: Medtech MVP 2021 Award Recipient
Venture Investing in a Post-COVID World
The Emergence of Data Science as a Core Medtech Pillar
1. Staying Abreast of the Cyberthreat LandscapeKeeping abreast of cyberthreats is challenging; however, an understanding of the most common cyber risks, and an awareness of current cyberthreat landscape by business leaders, alongside with use of tools and technologies designed for strengthening the security posture of their organizations, could help to avoid and mitigate against cyber risks
Provide an update on what is happening at FDA
Discuss the Pre-Submission program, the Breakthrough Device program, and the 510(k) program including FDA’s reshaping of it
3. Going Digital: How MedTech Can Meet Shifting Consumer ExpectationsConsumer receptivity to telemedicine and digital therapeutics has increased dramatically during the global COVID-19 pandemic, but significant barriers remain for patients, providers, and payers. Come discuss area where Digital MedTech is gaining traction, and keys to its persistence in a post-pandemic world.
View from the Beltway: What Should We Expect from the New Administration, FDA, and CMS?
Corporate Development Roundtable: What are Strategics Prioritizing in the New Normal?
Keynote 1:1 Executive Interview
2. FDA: A Pandemic Unto Itself?
